Ticker

Analyst Price Targets — A

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
July 6, 2026 12:38 pmVijay KumarEvercore ISI$148.00$128.34TheFly Agilent price target raised to $148 from $144 at Evercore ISI
June 11, 2026 9:50 amDavid WestenbergPiper Sandler$150.00$131.62TheFly Agilent initiated with a Neutral at Piper Sandler
June 3, 2026 9:27 amSidharth SahooHSBC$165.00$135.04TheFly Agilent price target lowered to $165 from $180 at HSBC
May 28, 2026 12:35 pmRBC Capital$155.00$133.51TheFly Agilent price target raised to $155 from $153 at RBC Capital
May 28, 2026 10:48 amRobert W. Baird$158.00$115.83TheFly Agilent price target raised to $158 from $156 at Baird
May 28, 2026 10:22 amBrandon CouillardWells Fargo$160.00$115.83StreetInsider Agilent (A) PT Lowered to $160 at Wells Fargo
May 26, 2026 8:12 pmDan LeonardRBC Capital$153.00$115.08TheFly Agilent initiated with an Outperform at RBC Capital
May 26, 2026 10:48 amCatherine Ramsey SchulteRobert W. Baird$156.00$114.96TheFly Agilent price target raised to $156 from $155 at Baird
April 14, 2026 10:41 amLuke SergottBarclays$140.00$117.52TheFly Agilent price target lowered to $140 from $150 at Barclays
March 9, 2026 1:27 pmFermium Research$150.00$114.21StreetInsider BofA Securities Reiterates Neutral Rating on Agilent (A) following Biocare Medical acquisition announcement

Latest News for A

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO®…

Business Wire • Jul 14, 2026
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a…

Business Wire • Jul 8, 2026
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA…

Business Wire • Jul 1, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top